HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Intranasal Poly-IC treatment exacerbates tuberculosis in mice through the pulmonary recruitment of a pathogen-permissive monocyte/macrophage population.

Abstract
Type I IFN has been demonstrated to have major regulatory effects on the outcome of bacterial infections. To assess the effects of exogenously induced type I IFN on the outcome of Mycobacterium tuberculosis infection, we treated pathogen-exposed mice intranasally with polyinosinic-polycytidylic acid condensed with poly-l-lysine and carboxymethylcellulose (Poly-ICLC), an agent designed to stimulate prolonged, high-level production of type I IFN. Drug-treated, M. tuberculosis-infected WT mice, but not mice lacking IFN-alphabeta receptor 1 (IFNalphabetaR; also known as IFNAR1), displayed marked elevations in lung bacillary loads, accompanied by widespread pulmonary necrosis without detectable impairment of Th1 effector function. Importantly, lungs from Poly-ICLC-treated M. tuberculosis-infected mice exhibited a striking increase in CD11b+F4/80+Gr1int cells that displayed decreased MHC II expression and enhanced bacterial levels relative to the same subset of cells purified from infected, untreated controls. Moreover, both the Poly-ICLC-triggered pulmonary recruitment of the CD11b+F4/80+Gr1int population and the accompanying exacerbation of infection correlated with type I IFN-induced upregulation of the chemokine-encoding gene Ccl2 and were dependent on host expression of the chemokine receptor CCR2. The above findings suggest that Poly-ICLC treatment can detrimentally affect the outcome of M. tuberculosis infection, by promoting the accumulation of a permissive myeloid population in the lung. In addition, these data suggest that agents that stimulate type I IFN should be used with caution in patients exposed to this pathogen.
AuthorsLis R V Antonelli, Antonio Gigliotti Rothfuchs, Ricardo Gonçalves, Ester Roffê, Allen W Cheever, Andre Bafica, Andres M Salazar, Carl G Feng, Alan Sher
JournalThe Journal of clinical investigation (J Clin Invest) Vol. 120 Issue 5 Pg. 1674-82 (May 2010) ISSN: 1558-8238 [Electronic] United States
PMID20389020 (Publication Type: Journal Article, Research Support, N.I.H., Intramural)
Chemical References
  • CD11b Antigen
  • Ccr2 protein, mouse
  • Interferon Type I
  • Receptors, CCR2
  • Polylysine
  • Interferon-beta
  • poly ICLC
  • Carboxymethylcellulose Sodium
  • Poly I-C
Topics
  • Administration, Intranasal
  • Animals
  • CD11b Antigen (biosynthesis)
  • Carboxymethylcellulose Sodium (analogs & derivatives, therapeutic use)
  • Dose-Response Relationship, Drug
  • Female
  • Interferon Type I (metabolism)
  • Interferon-beta (metabolism)
  • Lung (microbiology)
  • Macrophages (cytology)
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Monocytes (cytology)
  • Poly I-C (therapeutic use)
  • Polylysine (analogs & derivatives, therapeutic use)
  • Receptors, CCR2 (metabolism)
  • Tuberculosis (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: